Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Insilico Closes $37 Million Series B for AI Drug Discovery from China Investors

publication date: Sep 10, 2019

Insilico Medicine, a Hong Kong AI-based drug discovery company, closed a $37 million Series B funding round led by Qiming Venture Partners with other China investors participating. Last week Insilico published an article in Nature Biotechnology that detailed the company's search for novel molecules that target the discoidin domain receptor 1 (DDR1) pathway. The entire process moved from thousands of potential candidates to a final compound tested in mice in just 21 days. Insilico says the Series B will be used to commercialize its generative chemistry and target identification technology. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China